science
Japan to foster space industry competition, looking for next SpaceX
automated-news
Sen. John Cornyn, R-Texas, a key holdout on confirming Todd Blanche for attorney general, struck a deal to end the controversial "anti-weaponization fund."
Pascal Soriot has an awkward relationship with the UK. Now, the boss of AstraZeneca Plc is contemplating a megadeal with US peer Bristol-Myers Squibb Co. that could shift the British drugmaker’s center of gravity further westwards. It’s a potentially tricky tie-up. But Soriot’s counterintuitive bets
Pascal Soriot has an awkward relationship with the UK. Now, the boss of AstraZeneca Plc is contemplating a megadeal with US peer Bristol-Myers Squibb Co. that could shift the British drugmaker’s center of gravity further westwards. It’s a potentially tricky tie-up. But Soriot’s counterintuitive bets
automated-news
Sen. John Cornyn, R-Texas, a key holdout on confirming Todd Blanche for attorney general, struck a deal to end the controversial "anti-weaponization fund."
AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don’t like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss. (Source: Bloomberg)
Pascal Soriot has an awkward relationship with the UK. Now, the boss of AstraZeneca Plc is contemplating a megadeal with US peer Bristol-Myers Squibb Co. that could shift the British drugmaker’s center of gravity further westwards. It’s a potentially tricky tie-up. But Soriot’s counterintuitive bets
automated-news
The Bio-Pharma Industry and Society Listing Summary Please join the CSIS Global Health Policy Center on March 17, from 10:00am – 11:30am, for an exploration of how private bio-pharmaceutical firms can better support the critically important societal goals of improved affordability, access, quality,
automated-news
The Bio-Pharma Industry and Society Listing Summary Please join the CSIS Global Health Policy Center on March 17, from 10:00am – 11:30am, for an exploration of how private bio-pharmaceutical firms can better support the critically important societal goals of improved affordability, access, quality,
Jefferies ESG chief says investors overstate SpaceX governance risks